PuSH - Publikationsserver des Helmholtz Zentrums München

Liu, H.* ; Forouhar, F.* ; Seibt, T.* ; Saneto, R.* ; Wigby, K.* ; Friedman, J.* ; Xia, X.* ; Shchepinov, M.S.* ; Ramesh, S.K.* ; Conrad, M. ; Stockwell, B.R.*

Characterization of a patient-derived variant of GPX4 for precision therapy.

Nat. Chem. Biol. 18, 91-100 (2022)
Postprint DOI PMC
Open Access Green
Glutathione peroxidase 4 (GPX4), as the only enzyme in mammals capable of reducing esterified phospholipid hydroperoxides within a cellular context, protects cells from ferroptosis. We identified a homozygous point mutation in the GPX4 gene, resulting in an R152H coding mutation, in three patients with Sedaghatian-type spondylometaphyseal dysplasia. Using structure-based analyses and cell models, including patient fibroblasts, of this variant, we found that the missense variant destabilized a critical loop, which disrupted the active site and caused a substantial loss of enzymatic function. We also found that the R152H variant of GPX4 is less susceptible to degradation, revealing the degradation mechanism of the GPX4 protein. Proof-of-concept therapeutic treatments, which overcome the impaired R152H GPX4 activity, including selenium supplementation, selective antioxidants and a deuterated polyunsaturated fatty acid were identified. In addition to revealing a general approach to investigating rare genetic diseases, we demonstrate the biochemical foundations of therapeutic strategies targeting GPX4.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Cell-death; Selenium Supplementation; Oxidative Damage; Cancer-cells; Glutathione; Expression; Mutant; Dependency; Protects
ISSN (print) / ISBN 1552-4450
e-ISSN 1552-4469
Zeitschrift Nature Chemical Biology
Quellenangaben Band: 18, Heft: 1, Seiten: 91-100 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort Basingstoke
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Metabolism and Cell Death (MCD)
Förderungen U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
NINDS NIH HHS
NCI NIH HHS
U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)